IRAKLIA trial supports FDA approval of first anticancer therapy delivered via on-body injector

The U.S. Food and Drug Administration (FDA) recently approved an on-body injector for Sarclisa Escena® (isatuximab-irfc), making it the first anticancer therapy in the United States available through this type of wearable device. WIVR is proud to have served as a participating site for the IRAKLIA Phase 3 clinical trial that contributed to the evidence supporting this approval.